The stock of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) hit a new 52-week low and has $99.51 target or 8.00% below today’s $108.16 share price. The 7 months bearish chart indicates high risk for the $4.57B company. The 1-year low was reported on Oct, 13 by Barchart.com. If the $99.51 price target is reached, the company will be worth $365.60 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 101,071 shares traded hands. Taro Pharmaceutical Industries Ltd. (NYSE:TARO) has declined 21.61% since March 10, 2016 and is downtrending. It has underperformed by 29.13% the S&P500.
Analysts await Taro Pharmaceutical Industries Ltd. (NYSE:TARO) to report earnings on November, 1.
According to Zacks Investment Research, “Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals used in their production. Products are sold through wholesalers, generic drug distributors, drug store chains, mass merchandisers, HMOs, food stores, pharmacies and hospitals.”
More notable recent Taro Pharmaceutical Industries Ltd. (NYSE:TARO) news were published by: Forbes.com which released: “RSI Alert: Taro Pharmaceutical Industries (TARO) Now Oversold” on August 24, 2016, also Nasdaq.com with their article: “Taro Pharmaceutical Industries Becomes Oversold (TARO)” published on October 11, 2016, Seekingalpha.com published: “Taro Pharma: Seeking A Catalyst” on July 28, 2016. More interesting news about Taro Pharmaceutical Industries Ltd. (NYSE:TARO) were released by: Seekingalpha.com and their article: “Invest Like Vailshire: Taro Pharmaceutical Industries Ltd Is A Hidden Gem” published on September 30, 2015 as well as Seekingalpha.com‘s news article titled: “Taro Pharmaceutical Industries’ (TARO) CEO Kal Sundaram on Q4 2016 Results …” with publication date: May 27, 2016.
TARO Company Profile
Taro Pharmaceutical Industries Ltd. (Taro), incorporated on June 3, 1959, is a science pharmaceutical company. The Firm develops, makes and markets prescription (Rx) and over-the-counter (OTC) pharmaceutical products, primarily in the United States, Canada and Israel. Taro also develops and makes active pharmaceutical ingredients (APIs), primarily for use in its finished dosage form products. The Company’s primary areas of focus include semi-solids formulations, such as creams and ointments, and other dosage forms, such as liquids, capsules and tablets, primarily in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.